Celularity Inc. (NASDAQ:CELU) Short Interest Up 7.1% in December

Celularity Inc. (NASDAQ:CELU) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 395,600 shares, an increase of 7.1% from the December 15th total of 369,300 shares. Currently, 4.2% of the company’s stock are sold short. Based on an average trading volume of 1,080,000 shares, the days-to-cover ratio is currently 0.4 days.

Celularity Price Performance

Shares of NASDAQ CELU opened at $2.30 on Tuesday. The business’s 50-day simple moving average is $2.36 and its 200-day simple moving average is $2.61. Celularity has a 52 week low of $1.30 and a 52 week high of $7.97.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.